Yamada, Atsurou
Katsuki, Fujika http://orcid.org/0000-0002-0822-4776
Kondo, Masaki
Sawada, Hanayo
Watanabe, Norio
Akechi, Tatsuo
Funding for this research was provided by:
KAKENHI (16K12256)
Article History
Received: 19 September 2020
Accepted: 9 December 2020
First Online: 6 January 2021
Ethics approval and consent to participate
: This study was approved by the Ethics Review Committee of Nagoya City University Graduate School of Medical Sciences, Japan (Ref: No 60-17-0001). All participants provided written informed consent to the study.
: Not applicable.
: FK received speaker’s fees from Otsuka Pharmaceutical Co., Ltd. AY received medical fees from Gifu Hospital, speaker’s fees from Aichi Education and Sports foundation, Kyowa Pharmaceutical Industry Co., Ltd., Meiji Seika Pharma Co., Ltd., Mental Care Association Japan, Mochida Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and other fees from Nagoya City. AY received grants from the Japanese Ministry of Education, Science, and Technology. HS declares no conflicts of interest. MK reports a grant from the Japanese Ministry of Education, Science, and Technology, grants from Novartis Pharma K.K., personal fees from Shinogi & Co., Ltd., and personal fees from Yoshitomiyakuhin Corporation, outside the submitted work. TA has received lecture fees from Astellas Pharma Inc., AstraZeneca K.K., Daiichi Sankyo Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Eisai Co., Ltd., Hisamitsu Pharmaceutical Co., Inc., Janssen Pharmaceutical K.K., Kyowa Kirin Co., Ltd., Kyowa Pharmaceutical Industry Co., Ltd., Eli Lilly Japan K.K., MSD K.K., Meiji Seika Pharma Co., Ltd., Mochida Pharmaceutical Co., Ltd., Mundipharma K.K., Nipro, Otsuka Pharmaceutical Co. Ltd., Pfizer Japan Inc., Shionogi & Co., Ltd., Terumo, and Tsumura & Co., Ltd. TA has received research funds from Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., FUJIFILM RI Pharma Co., Ltd., Eli Lilly Japan K.K., MSD K.K., Novartis Pharma K.K., Otsuka Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Mitsubishi Tanabe Pharma Corporation. NW has received royalties from Sogensha, Medical View, and Advantage Risk Management for writings.